Bone Marrow Negative Visceral Leishmaniasis in an Adolescent Male

Por Jetley, S, Rana, S, Khan, S, Zeeba, JS, Hassan, MJ, Kapoor, P
Publicado em 2013

Global end-diastolic volume an emerging preload marker vis-a-vis other markers - Have we reached our goal?

Por Kapoor, P. M, Bhardwaj, Vandana, Sharma, Amita, Kiran, Usha
Publicado no Ann Card Anaesth (2016)

Prevalence and epidemiology of Salmonella enterica serovar Gallinarum from poultry in some parts of Haryana, India

Por Arora, Devan, Kumar, Suresh, Jindal, Naresh, Narang, Gulshan, Kapoor, P. K., Mahajan, N. K.
Publicado no Vet World (2015)

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy

Por Siontis, B, Kumar, S, Dispenzieri, A, Drake, M T, Lacy, M Q, Buadi, F, Dingli, D, Kapoor, P, Gonsalves, W, Gertz, M A, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma

Por Srivastava, G, Rana, V, Lacy, MQ, Buadi, FK, Hayman, SR, Dispenzieri, A, Gertz, MA, Dingli, D, Zeldenrust, S, Russell, S, McCurdy, A, Kapoor, P, Kyle, R, Rajkumar, SV, Kumar, S
Publicado em 2013

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era

Por Chakraborty, R, Muchtar, E, Kumar, S K, Jevremovic, D, Buadi, F K, Dingli, D, Dispenzieri, A, Hayman, S R, Hogan, W J, Kapoor, P, Lacy, M Q, Leung, N, Gertz, M A
Publicado no Blood Cancer J (2016)

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Por Majithia, N, Rajkumar, SV, Lacy, MQ, Buadi, FK, Dispenzieri, A, Gertz, MA, Hayman, SR, Dingli, D, Kapoor, P, Hwa, L, Lust, JA, Russell, SJ, Go, RS, Kyle, RA, Kumar, SK
Publicado no Leukemia (2016)

Prevalence, incidence and survival of smoldering multiple myeloma in the United States

Por Ravindran, A, Bartley, A C, Holton, S J, Gonsalves, W I, Kapoor, P, Siddiqui, M A, Hashmi, S K, Marshall, A L, Ashrani, A A, Dispenzieri, A, Kyle, R A, Rajkumar, S V, Go, R S
Publicado no Blood Cancer J (2016)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

Por Ravi, P, Kumar, S, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R S, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado no Blood Cancer J (2017)

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

Por Gonsalves, W I, Leung, N, Rajkumar, S V, Dispenzieri, A, Lacy, M Q, Hayman, S R, Buadi, F K, Dingli, D, Kapoor, P, Go, R S, Lin, Y, Russell, S J, Lust, J A, Zeldenrust, S, Kyle, R A, Gertz, M A, Kumar, S K
Publicado no Blood Cancer J (2015)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

Por Ravi, P, Kumar, S, Larsen, J T, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado no Blood Cancer J (2016)

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death

Por Warsame, R, Kumar, S K, Gertz, M A, Lacy, M Q, Buadi, F K, Hayman, S R, Leung, N, Dingli, D, Lust, J A, Ketterling, R P, Lin, Y, Russell, S, Hwa, L, Kapoor, P, Go, R S, Zeldenrust, S R, Kyle, R A, Rajkumar, S V, Dispenzieri, A
Publicado no Blood Cancer J (2015)

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

Por Binder, M, Rajkumar, S V, Ketterling, R P, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K
Publicado no Blood Cancer J (2016)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

Por Binder, M, Rajkumar, S V, Ketterling, R P, Greipp, P T, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K
Publicado no Blood Cancer J (2017)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

Por Kumar, S K, LaPlant, B, Roy, V, Reeder, C B, Lacy, M Q, Gertz, M A, Laumann, K, Thompson, M A, Witzig, T E, Buadi, F K, Rivera, C E, Mikhael, J R, Bergsagel, P L, Kapoor, P, Hwa, L, Fonseca, R, Stewart, A K, Chanan-Khan, A, Rajkumar, S V, Dispenzieri, A
Publicado no Blood Cancer J (2015)

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma

Por Tandon, N, Rajkumar, S V, LaPlant, B, Pettinger, A, Lacy, M Q, Dispenzieri, A, Buadi, F K, Gertz, M A, Hayman, S R, Leung, N, Go, R S, Dingli, D, Kapoor, P, Lin, Y, Hwa, Y L, Fonder, A L, Hobbs, M A, Zeldenrust, S R, Lust, J A, Gonsalves, W I, Russell, S J, Kumar, S K
Publicado no Blood Cancer J (2017)